BACKGROUND: Endoscopic guided biopsy (EGB) is performed after an initial endoscopy for the investigation of patients with suspected nasopharyngeal carcinoma (NPC). The aim of the study was to determine whether MR imaging has the potential to replace invasive EGB in patients with a normal endoscopy. PATIENTS AND METHODS: Data from 2 groups of patients was reviewed, group 1 with proved NPC for MR staging (n = 456) and group 2 with suspected NPC (n = 77). The sensitivity was calculated for group 1 and sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy for group 2. RESULTS: In group 1, which included 118 of 456 (26%) with stage 1 disease, cancer was detected in all patients, giving a sensitivity of 100%. In group 2, MR imaging was negative for NPC in 70 (91%) patients, and no cancer has been detected on follow-up (follow-up range, 1-90 months; mean, 36 months). MR imaging was positive for NPC in 7 (9%) patients and NPC was confirmed by biopsy in 3 (4%). Two of these 3 patients had undergone negative endoscopy and biopsy before the MR imaging. NPC was not present in the remaining 4 patients, 2 of whom were found to have lymphoid hyperplasia. MR imaging had a sensitivity of 100%, specificity of 95%, NPV of 100%, PPV of 43%, and accuracy of 95%. CONCLUSION: MR imaging has the potential to screen healthy patients who do not require EGB and direct the site of biopsy in small cancers that may be missed by endoscopy. On the basis of these results, a prospective study is planned.
BACKGROUND: Endoscopic guided biopsy (EGB) is performed after an initial endoscopy for the investigation of patients with suspected nasopharyngeal carcinoma (NPC). The aim of the study was to determine whether MR imaging has the potential to replace invasive EGB in patients with a normal endoscopy. PATIENTS AND METHODS: Data from 2 groups of patients was reviewed, group 1 with proved NPC for MR staging (n = 456) and group 2 with suspected NPC (n = 77). The sensitivity was calculated for group 1 and sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy for group 2. RESULTS: In group 1, which included 118 of 456 (26%) with stage 1 disease, cancer was detected in all patients, giving a sensitivity of 100%. In group 2, MR imaging was negative for NPC in 70 (91%) patients, and no cancer has been detected on follow-up (follow-up range, 1-90 months; mean, 36 months). MR imaging was positive for NPC in 7 (9%) patients and NPC was confirmed by biopsy in 3 (4%). Two of these 3 patients had undergone negative endoscopy and biopsy before the MR imaging. NPC was not present in the remaining 4 patients, 2 of whom were found to have lymphoid hyperplasia. MR imaging had a sensitivity of 100%, specificity of 95%, NPV of 100%, PPV of 43%, and accuracy of 95%. CONCLUSION: MR imaging has the potential to screen healthy patients who do not require EGB and direct the site of biopsy in small cancers that may be missed by endoscopy. On the basis of these results, a prospective study is planned.
Authors: Sing-Fai Leung; John S Tam; Anthony T C Chan; Benny Zee; Lisa Y S Chan; Dolly P Huang; Andrew Van Hasselt; Philip J Johnson; Y M Dennis Lo Journal: Clin Chem Date: 2003-12-18 Impact factor: 8.327
Authors: Wai-Tong Ng; Tsz-Kok Yau; Raymond W H Yung; Wai-Man Sze; Abby H L Tsang; Ada L Y Law; Anne W M Lee Journal: Int J Cancer Date: 2005-03-01 Impact factor: 7.396
Authors: Raymond K Y Tsang; Alexander C Vlantis; Ricky W K Ho; John S L Tam; K F To; C Andrew van Hasselt Journal: Head Neck Date: 2004-07 Impact factor: 3.147
Authors: A D King; A C Vlantis; T W C Yuen; B K H Law; K S Bhatia; B C Y Zee; J K S Woo; A T C Chan; K C A Chan; A T Ahuja Journal: AJNR Am J Neuroradiol Date: 2015-08-27 Impact factor: 3.825
Authors: A D King; L Y S Wong; B K H Law; K S Bhatia; J K S Woo; Q-Y Ai; T Y Tan; J Goh; K L Chuah; F K F Mo; K C A Chan; A T C Chan; A C Vlantis Journal: AJNR Am J Neuroradiol Date: 2017-12-28 Impact factor: 3.825
Authors: A D King; J K S Woo; Q-Y Ai; F K F Mo; T Y So; W K J Lam; I O L Tse; A C Vlantis; K W N Yip; E P Hui; B B Y Ma; R W K Chiu; A T C Chan; Y M D Lo; K C A Chan Journal: AJNR Am J Neuroradiol Date: 2020-03 Impact factor: 3.825